Table 4.

Treatment outcomes among patients with overactive bladder who failed the initial overactive bladder medication and switched to a different mode of medication*

	Mode of switch of OAB medication	n	Successful, n (%)	Failure, n (%)	P
Switch OAB medication	From solifenacin to mirabegron 50 mg QD	5s1	28 (54.9)	23 (45.1)	0.181
	From mirabegron to solifenacin 5 mg QD	47	32 (68.1)	15 (31.9)
Solifenacin 5 mg+mirabegron 25 mg	Switch to solifenacin 5 mg QD alone	11	6 (54.5)	5 (45.5)	0.084
	Switch to mirabegron 50 mg alone	16	14 (87.5)	2 (12.5)
Add-on≥2 OAB medications	From solifenacin to add-on≥2 anti-M	27	14 (51.9)	13 (48.1)	0.357
	From mirabegron to add-on≥2 anti-M	33	21 (63.6)	12 (36.4)
Total		185	115 (62.2)	70 (37.8)

*Excluding 65 patients who failed the initial medication but did not switch to other mode of treatment. Anti-M: antimuscarinic agent, OAB: Overactive bladder